Reported Consolidated quarterly numbers for Glenmark Pharma are:
Net Sales at Rs 3,062.95 crore in March 2024 down 9.21% from Rs. 3,373.72 crore in March 2023.
Story continues below Advertisement
Quarterly Net Loss at Rs. 1,218.28 crore in March 2024 down 184.44% from Rs. 428.30 crore in March 2023.
EBITDA stands at Rs. 1,277.51 crore in March 2024 up 126.21% from Rs. 564.75 crore in March 2023.
Glenmark shares closed at 1,119.45 on May 27, 2024 (NSE) and has given 45.19% returns over the last 6 months and 88.30% over the last 12 months.
Story continues below Advertisement
| Glenmark Pharma | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Mar'24 | Dec'23 | Mar'23 | | Net Sales/Income from operations | 3,062.95 | 2,506.70 | 3,300.61 | | Other Operating Income | -- | -- | 73.10 | | Total Income From Operations | 3,062.95 | 2,506.70 | 3,373.72 | | EXPENDITURE | | Consumption of Raw Materials | 754.31 | 657.51 | 876.80 | | Purchase of Traded Goods | 210.80 | 413.11 | 230.39 | | Increase/Decrease in Stocks | 30.42 | -38.35 | 84.92 | | Power & Fuel | -- | -- | -- | | Employees Cost | 700.96 | 753.04 | 657.58 | | Depreciation | 151.34 | 147.08 | 146.53 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 862.13 | 930.05 | 919.06 | | P/L Before Other Inc., Int., Excpt. Items & Tax | 353.01 | -355.72 | 458.43 | | Other Income | 773.17 | 45.41 | -40.21 | | P/L Before Int., Excpt. Items & Tax | 1,126.17 | -310.31 | 418.22 | | Interest | 148.56 | 134.34 | 109.26 | | P/L Before Exceptional Items & Tax | 977.61 | -444.66 | 308.96 | | Exceptional Items | -446.78 | -76.72 | -799.73 | | P/L Before Tax | 530.83 | -521.38 | -490.77 | | Tax | 1,769.47 | -71.80 | -87.63 | | P/L After Tax from Ordinary Activities | -1,238.65 | -449.58 | -403.14 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | 24.38 | 118.77 | -- | | Net Profit/(Loss) For the Period | -1,214.27 | -330.82 | -403.14 | | Minority Interest | -4.01 | -20.56 | -25.17 | | Share Of P/L Of Associates | -- | -- | -- | | Net P/L After M.I & Associates | -1,218.28 | -351.38 | -428.30 | | Equity Share Capital | 28.22 | 28.22 | 28.22 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -43.18 | -12.45 | -15.18 | | Diluted EPS | -43.18 | -12.45 | -15.18 | | EPS After Extra Ordinary | | Basic EPS | -43.18 | -12.45 | -15.18 | | Diluted EPS | -43.18 | -12.45 | -15.18 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
